Wall Street analyst estimates for Cabaletta Bio, Inc. (CABA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 10 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.83 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-0.33 | ||
| 2026-08-13 | $-0.34 | $-0.37 | +8.8% |
| 2026-05-14 | $-0.39 | $-0.41 | +4.9% |
| 2026-03-23 | $-0.40 | $-0.45 | +11.1% |
| 2025-11-10 | $-0.44 | $-0.49 | +10.2% |
| 2025-08-07 | $-0.73 | $-0.71 | -2.8% |
| 2025-05-15 | $-0.71 | $-0.67 | -6.0% |
| 2025-03-31 | $-0.65 | $-0.65 | +0.0% |
Valuation Ratios
| Price / Book | 1.41 |
| EV / EBITDA | -1.39 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | 0 | $4.5M | $11.7M | $21.4M | $32.5M | $39.3M | $55.4M | $97.2M | $142.7M |
| Selling, General & Admin | $250000 | $1.7M | $7.0M | $12.5M | $13.8M | $14.8M | $19.2M | $27.9M | $29.6M |
| Operating Expenses | $250000 | $6.2M | $18.7M | $33.8M | $46.3M | $54.1M | $74.7M | $125.1M | $172.2M |
| Operating Income | -$250000 | -$6.2M | -$18.7M | -$33.8M | -$46.3M | -$54.1M | -$74.7M | -$125.1M | -$172.2M |
| EBITDA | $83333 | -$6.0M | -$18.6M | -$33.0M | -$45.6M | -$51.8M | -$66.2M | -$113.4M | -$164.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $748000 | $2.0M |
| Pre-tax Income | -$250000 | -$12.2M | -$16.9M | -$33.3M | -$46.3M | -$53.0M | -$67.7M | -$115.9M | -$167.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$250000 | -$12.2M | -$16.9M | -$33.3M | -$46.3M | -$53.0M | -$67.7M | -$115.9M | -$167.9M |
| EPS | $-0.01 | $-0.84 | $-4.07 | $-1.44 | $-1.80 | $-1.81 | $-1.65 | $-2.34 | $-1.64 |
| EPS (Diluted) | $-0.01 | $-0.84 | $-4.07 | $-1.44 | $-1.80 | $-1.81 | $-1.65 | $-2.34 | $-1.64 |
| Shares Outstanding (Diluted) | $24.0M | $14.5M | $5.5M | $23.1M | $25.7M | $29.3M | $40.9M | $49.5M | $102.3M |
Price
| Price | $2.49 |
| Market Cap | $406M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALLO · AVIR · CAPR · EDIT · HUMA · IMMP · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CABA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks